Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the Treatment of Unresectable, Locally Advanced or Metastatic Biliary Tract Cancers With FGFR2 Alterations (clinicaltrials.gov) - Sep 4, 2026 - P2 | N=29 | Recruiting | Sponsor: Ohio State University Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting
Enrollment open • Ampulla of Vater Carcinoma • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor • FGFR2
|